Ozempic Gastroparesis Settlement: Understanding the Criteria

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

Legacy of General Health and Science Information

For decades, the Immunodeficiency Foundation has served as a trusted repository for general health and science information, preserving a broad legacy of knowledge that spans foundational immunology, public health awareness, and the evolving understanding of human physiology. This heritage reflects a commitment to documenting how medical science intersects with patient experience, always within a framework of rigorous, neutral reporting. As part of that ongoing mission, the Foundation now turns its attention to a contemporary area of public health concern: the transition from general health contexts to specific exposures that may carry unintended consequences. In recent years, widespread use of glucagon-like peptide-1 receptor agonists, such as Ozempic, has prompted careful scrutiny of their safety profiles beyond metabolic effects. One emerging focus involves reports of gastroparesis—a condition of delayed gastric emptying—among individuals with prior or current exposure to these medications. This shift in focus does not imply causation, but rather reflects a responsible expansion of the Foundation’s archival scope to include documented patient experiences and regulatory discussions. By bridging from general health science to this specific exposure concern, the Foundation continues its tradition of providing balanced, evidence-informed reference material for clinicians, researchers, and the public.

Bridging to Specific Exposure Concerns

Building on its legacy of documenting the intersection of medical science and patient experience, the Foundation now examines the specific relationship between Ozempic (semaglutide) and gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, which contributes to glycemic control but also underlies gastrointestinal adverse effects. Evidence from clinical trials demonstrates that gastrointestinal adverse reactions occur significantly more frequently among patients receiving Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: Disease Overview and Diagnosis

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where a radiolabeled meal is tracked over time, with retention of more than 10% at four hours considered diagnostic. The condition can severely impair quality of life and nutritional status, and its management often includes dietary modifications, prokinetic agents, and antiemetics. While gastroparesis is not explicitly listed in the Ozempic trial data, the pharmacodynamic effect of delayed gastric emptying is a known consequence of GLP-1 receptor agonism, and the reported symptoms—nausea, vomiting, dyspepsia, and gastroesophageal reflux—are consistent with gastroparesis presentation. The mechanistic pathway linking Ozempic to gastroparesis involves its action on GLP-1 receptors in the gastrointestinal tract, which inhibits gastric motility and slows gastric emptying. This effect is dose-dependent and can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The timeline between exposure and documented harm typically begins during dose escalation, as most gastrointestinal adverse reactions occur in this period, though symptoms may persist or worsen with continued use.

Risk Context and Settlement Considerations

Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but does not specifically mention gastroparesis as a potential adverse effect. This gap may affect informed consent and patient awareness. For affected patients, settlement-related considerations hinge on demonstrating a causal link between Ozempic use and the development of gastroparesis, supported by temporal association and exclusion of other causes. The timeline between exposure and documented harm is crucial; patients who developed symptoms during dose escalation or shortly after initiation may have stronger claims. In summary, the evidence indicates that Ozempic is associated with a significantly increased risk of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic basis is well-established, and the timing of symptoms aligns with drug exposure. Patients who have developed gastroparesis after using Ozempic should consider consulting legal counsel to evaluate potential settlement criteria, which typically require medical documentation of diagnosis, evidence of Ozempic use, and a plausible timeline linking the two.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, where retention of more than 10% of a radiolabeled meal at four hours is considered diagnostic.

What evidence links Ozempic to gastroparesis?

Clinical trials show that gastrointestinal adverse reactions occur significantly more frequently with Ozempic than placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed, the pharmacodynamic effect of delayed gastric emptying is a known consequence of GLP-1 receptor agonism, and reported symptoms are consistent with gastroparesis.

What are the settlement criteria for Ozempic-related gastroparesis?

Settlement criteria typically require medical documentation of a gastroparesis diagnosis, evidence of Ozempic use, and a plausible timeline linking the two. Patients who developed symptoms during dose escalation or shortly after initiation may have stronger claims. Consulting legal counsel is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.